Emerging strategies for the treatment of atherosclerosis as seen from the patent literature.
Suckling
K E
KE
SmithKline Beecham Pharmaceuticals, Welwyn, Herts, U.K.
D000924:Anticholesteremic Agents / Q000737:chemistry / Q000627:therapeutic use*; D000975:Antioxidants / Q000737:chemistry / Q000627:therapeutic use*; D001161:Arteriosclerosis / Q000188:drug therapy*; D015195:Drug Design; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D010330:Patents as Topic; D002785:Sterol O-Acyltransferase / Q000037:antagonists & inhibitors
D000924:Anticholesteremic Agents; D000975:Antioxidants; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002785:Sterol O-Acyltransferase